tbuckley/cabot-search huggingface dataset:
The prevalence of CDK12 alterations in Chinese cancer patients and the association with tumor mutation burden(TMB) and survival.
Authors: Ke Li, Xi Guo, Yunhua Mao, Mengmei Yang, Mengli Huang, Wenzhuan Xie, Xinyi Liu, Dejuan Wang, Jianguang Qiu, Xiongbing Zu
Journal: Journal of Clinical Oncology (2020)

e13663 Background: Cyclin-dependent kinase 12 (CDK12) is a cyclin-dependent kinase that regulates transcription and RNA splicing, thereby modulating multiple cellular processes. It has been suggested that CDK12 loss-of-function mutations lead to a higher neoantigen burden and favorable responses to PD-1 inhibitors in advanced prostate cancer. Given this potentially actionable molecular subtype, we sought to determine the prevalence of CDK12 alterations in Chinese cancer patients and the association with TMB and overall survival(OS). Methods: The prevalence of CDK12 alterations were queried in 3D Medicines database with 15,745 Chinese cancer patients involved. Whole-exome sequencing data of 464 patients with prostate adenocarcinoma(PRAD) from the Cancer Genome Altas (TCGA) were downloaded to explore the association between CDK12 gene alteration and OS. And the association with TMB were analyzed in a cohort of 731 patients with various cancer types published by Memorial Sloan Kettering (MSKCC) (Samstein et al., Nature Genetics, 2019). Results: Any CDK12 and known or likely deleterious CDK12 mutations were identified in 598(3.8%) and 98(0.62%) patients, respectively. Across all cancer types, prostate adenocarcinoma(PRAD) was found to have the highest frequency of deleterious mutations(8.75%, 23/263), followed by breast cancer (4.97%, 25/503). Mutations were also detected in multiple cancer types including bladder cancer, ovarian cancer, lung cancer, colorectal cancer and so on with a frequency of less than 1%. CDK12 mutations were associated with shorter OS (HR = 15.25; 95% CI, 2.88-80.73; p &lt; 0.001) in TCGA PRAD and cholangiocarcinoma datasets, which was not seen in other cancer types. Patients harboring CDK12 mutation had a significant higher TMB(p &lt; 0.001) in the pan-cancer study of publicly-available cohort from MSKCC. Conclusions: CDK12 alterations existed across tumor types in Chinese patients with relatively high frequencies detected in PRAD and breast cancer and represent extremely rare events in multiple cancers. CDK12 mutation was a poor prognostic factor in PRAD and cholangiocarcinoma. In a pan cancer analysis patients with CDK12 mutation tended to have a significant higher TMB and may benefit from PD-1/L1 blockade immunotherapy.
Real-world experience with Lenvatinib in the management of Hepatocellular Carcinoma: A single-center Indian experience.
Authors: Amit Rauthan, S.P. Somashekhar, Poonam Patil, Shabber Zaveri
Journal: Journal of Clinical Oncology (2020)

e16596 Background: Sorafenib has been the standard first line treatment for more than a decade in advanced Hepatocellular carcinoma (HCC) patients. Lenvatinib is a novel oral tyrosine kinase inhibitor which inhibits VEGF receptors 1-3, FGF receptors 1-4, PDGF receptor alpha, RET and KIT, and has activity in multiple cancers. In the recent phase III REFLECT trial, Lenvatinib was non-inferior to Sorafenib in the first line management of advanced HCC. It showed better response rates, improved progression free survival (PFS) with similar overall survival (OS). There is no data of Lenvatinib in Indian patients. Methods: This is a single center, retrospective study, which included patients with metastatic or unresectable HCC who received treatment with Lenvatinib at our center. The endpoints were objective response rate (ORR), PFS and toxicity. Results: 31 patients received Lenvatinib from Dec 2017 to Oct 2019. Patients greater than 60kg received 12mg/day and those less than 60kg received 8mg/day. There were 5 females and 26 males. Median age was 60 years (29-78 years). All patients were BCLC stage C. Child Pugh score was A in 20 patients, B in 9 patients and C in 2 patients. AFP was elevated in 25 (80.6%) patients. 26 patients received Lenvatinib as initial therapy, 3 received it after Sorafenib progression, and 2 received after Sorafenib and Nivolumab progression. 6 patients (19.35%) achieved partial response (PR), 12 (38.7%) had stable disease and 13 (41.9%) had progressive disease by recist criteria. ORR was 19.35% and disease control rate was 58%. 2 patients underwent TACE after achieving PR. The median PFS was 7 months. The common adverse events were hypertension, weight loss, palmar plantar rashes, dysphonia and fatigue. Grade 3 AEs occurred in 8 patients (25.8%). 10 patients (32.2%) required dose reduction due to side effects. Conclusions: Lenvatinib has demonstrated a high response rate and disease control rate in our patients. Achieving a PFS of 7 months is an improvement over our previous Sorafenib experience. Further followup will demonstrate the overall survival. It is well tolerated and most side effects can be managed with patient education. The major advantage has been that in contrast to Sorafenib, only 32.2% patients required dose reduction due to side effects. These results are practice changing and Lenvatinib has become our first line regimen in advanced HCC. Lenvatinib would provide a good backbone to combine immunotherapy as first line treatment in future.
2型糖尿病患者高同型半胱氨酸血症对转化生长因子β1和尿微量白蛋白的影响
Authors: 岳红, 柳洁, 邵晋康, 杨平安, 秦洁, 杨艳兰, 张美兰, 张丽杰
Journal: BMJ (2007)

将96例伴高同型半胱氨酸(Hcy)血症的2型糖尿病患者分为4组,分别予叶酸、甲钴胺、叶酸+甲钴胺+VitB6及不予VitB处理,观察血浆Hcy、转化生长因子β1(TGF-β1)和尿微量白蛋白/肌酐(MAlb/Cr)的水平.结果,叶酸、甲钴胺、叶酸+甲钴胺+VitB6治疗后Hcy、TGF-β1、MAlb/Cr水平均明显下降.提示,补充叶酸、甲钴胺、维生素B6可降低血浆Hcy、TGF-β1、尿MAlb/Cr的水平。
A systems medicine-based approach for finding metabolic targets applied to primary basal-like breast cancer.
Authors: Daniel Cook, Jens Nielsen, Eduardo Braun
Journal: Journal of Clinical Oncology (2020)

e12590 Background: Although metabolic disfunction is one of the hallmarks of cancer and metabolism-based therapies are a key class of chemotherapeutics, there remains no systematic way to identify metabolism-based targets for therapeutic intervention. Because of this deficiency, metabolism-based therapies offer a largely untapped area for therapeutic discovery, especially for difficult to target tumors, like basal-like breast cancer (BLBC). Adding to the challenge of discovering metabolism-based therapeutics for BLBC, however, is the heterogeneity of tumor behavior across patients, both in terms of aggressiveness and molecular regulation. Methods: We addressed these challenges by introducing a systems medicine-based technique integrating metabolic network modeling with single-patient RNA-sequencing (RNA-seq). We then applied this technique to investigate metabolic weaknesses in primary BLBC. We constructed a genome-scale metabolic model of breast cancer (ecBRCA) along with RNA-seq profiles constructed from The Cancer Genome Atlas (TCGA) to predict metabolic targets whose inhibition is lethal to BLBC tumors. We then evaluated the effectiveness of drugging these targets across patients by simulating the effect of a targeted knock-out on primary tumors with published RNA-seq profiles from 534 BLBC patients in TCGA and the Swedish Cancerome Analysis Network for Breast (SCANB). Results: We found multiple metabolic targets that may prove clinically useful for complementary treatment of primary BLBC tumors. Among these, we found UDP-Glucose 6-Dehydrogenase (UGDH) and Heparan Sulfate 2-O-Sulfotransferase 1 (HS2ST1) to be particularly promising protein targets for chemotherapy in BLBC, with 80-100% of simulated BLBC tumors responding to their inhibition. Currently FDA-approved drugs down-regulating these proteins, such as metformin (for UGDH) and surfen (for HS2ST1), are potentially viable complementary treatments for BLBC patients. Additionally, we found several metabolite targets whose inhibition may inhibit BLBC growth, including leukotriene A4, creatinine, vitamin D3, and the oncometabolites 2- and 3-hydroxy-glutarate. Conclusions: Taking a systems medicine-based approach to understanding BLBC metabolism allows for a systematic way to identify metabolic targets for therapeutic intervention. Additionally, certain metabolic weaknesses appear to be conserved in BLBC tumors across patients, including a dependence on UGDH and HS2ST1, which could be treated with currently available drugs like metformin and surfen.
Patient controlled analgesia (PCA) vs non-PCA intravenous hydromorphone titration for severe cancer pain: A multi-center, phase III trial, HMORCT09-1.
Authors: Rongbo Lin, Sunzhi Lin, Jinfeng Zhu, Shuitu Feng, Qingyi Wu, Jianqian Fu, Fang Wang, Hui Li, Xiaofeng Li, Gaowang Zhang, Yongzhi Yao, Min Xin, Tianyang Lai, Xia Lv, Yigui Chen, Yubiao Lin, Lixia Hong, Shaowei Lin, Shen Zhao, Cheng Huang
Journal: Journal of Clinical Oncology (2020)

12078 Background: The titration of opioid dosage is necessary for adequate pain relief with acceptable side effects among individuals with cancer pain. The titration process can be achieved by non-patient administration or PCA pump. The aim of this study was to evaluate the efficacy of PCA versus non-PAC titration for severe cancer pain. Methods: Patients with severe cancer pain (NRS ≥ 7/10 at rest) were randomized into PCA or non-PCA titration and stratified by opioid tolerance or intolerance. For PCA, the pump was set as no continuous dose, hydromorphone bolus dose was 10%-20% of the total equianalgesic of past 24h for opioid tolerance, or 0.5 mg for opioid intolerance. The lockout time was 15 min. For non-PCA, initial hydromorphone bolus was the same with PCA. Reassess pain at 15 min. The dose of hydromorphone was increased by 50%-100% if pain unchanged or increased, or repeated if NRS was 4-6, or continue at current dose as needed if NRS≤3. The primary endpoint was the time to successful titration (TST) - time from start to the time of pain controlled at NRS ≤ 3 in two consecutive evaluation with 15-min intervals, which was tested by K-M curve. Results: A total of 214 patients were randomized (106 in PCA, 108 in non-PCA) in 17 study sites. The most common sites of primary cancer were lung (21.03%), stomach (15.89%), colorectal (14.49%) etc. Median TSTs were 0.50h in PCA, 0.79h in non-PCA, HR 1.64 (95% CI 1.23, 2.17, P = 0.00127). In opioid tolerance, 0.50h in PCA, 1.00h in non-PCA (HR 1.92, 95% CI 1.32, 2.78, P = 0.0025). while in opioid intolerance, 0.50h in PCA and 0.50 in non-PCA (HR 1.35, 95% CI 0.88, 2.04, P = 0.162). The median dosage of hydromorphone for TST was 1.00mg (P 25 , P 75 0.50, 2.00) in PCA, 1.50mg (P 25 , P 75 1.00, 2.50) in non-PCA (P = 0.086). In opioid tolerance, 1.00mg (P 25 , P 75 1.00, 2.00) in PCA, 2.00mg (P 25 , P 75 1.00, 4.00) in non-PCA (P = 0.009). In opioid intolerance, 1.00mg (P 25 , P 75 0.50, 2.00) in PCA and 1.00 mg (P 25 , P 75 0.50, 2.00) non-PCA (P = 0.793). Mean patient satisfaction assessed by ESAS score was significantly superior in PCA to non-PCA (0.62±0.67 vs 1.27±0.98 for ITT, 0.66±0.66 vs 1.39±1.00 for opioid tolerance, and 0.56±0.69 vs 1.13±0.95 for opioid intolerance). Adverse events were similar in both PCA/non-PCA groups. Conclusions: PCA IV hydromorphone titration provided quicker analgesic effect, higher patients satisfaction, and a similar tolerability as compared to non-PCA administration in patients with severe cancer pain. Clinical trial information: NCT03375515 .
Genomic correlates and classification of PD-L1 status in non-small cell lung cancer.
Authors: Feng Liang, Sisi Liu, Ya Jiang, Xiuxiu Xu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Xingsheng Hu
Journal: Journal of Clinical Oncology (2020)

e21578 Background: Programmed cell death 1 (PD-L1) is the first FDA-approved predictive biomarker for non-small cell lung cancer (NSCLC) patients treated with PD-(L)1 blockade therapy. Herein, we aim to identify potential anti-PD-L1 treatment-related biomarkers through evaluating the correlation between the PD-L1 expression level, clinical characteristics, and the mutational profile of a large Chinese NSCLC cohort. Methods: Genomic profiling of tumor biopsies from a total of 808 Chinese NSCLC patients, including 651 adenocarcinomas (ADCs) and 157 squamous cell carcinomas (SCCs), was performed using next-generation sequencing by targeting 425 cancer-relevant genes. Immunohistochemical analysis was used to evaluate PD-L1 protein expression using PD-L1 antibodies including DAKO 22C3 ( N= 695) and DAKO 28-8 ( N= 113), respectively. Results: The PD-L1 positive ( &gt; 1%) rate was 49.2% in ADCs and 52.9% in SCCs, respectively. PD-L1 expression (22C3) was associated with the male gender( p&lt; 0.01) and lymph node metastasis ( p= 0.048) in ADCs but not in SCC patients. PD-L1 expression (22C3) was inversely correlated with KRAS wildtype ( p&lt; 0.001) and EGFR exon 19 deletion( p&lt; 0.01) in ADC, while it was negatively associated with TP53 oncogenic mutations ( p= 0.049) in SCC. Copy number variation analysis revealed that MDM2 amplification ( p= 0.027), 1q gain ( p= 0.012), and 5q deletion ( p&lt; 0.01) negatively correlated with PD-L1 expression, whereas PD-L1 and PD-L2 amplification ( p&lt; 0.001 and p&lt; 0.0001) were positively associated with PD-L1 expression in ADCs. In SCCs, PD-L1 expression (22C3) was negatively associated with copy number gain in EGFR ( p= 0.040), MDM2 ( p= 0.044), 14q ( p= 0.032), and 20q ( p= 0.026), along with PTPRD loss (p = 0.015) and 19p deletion (p = 0.025). However, it was positively associated with 9p amplification ( p&lt; 0.01) and 13q deletion ( p= 0.019). Plus, KIF5B- RET ( p= 0.006) appeared to be inversely related to the PD-L1 expression levels (22C3) in ADCs alone. In addition, these predicted biomarkers were used to delineate the receiver operating characteristic (ROC) calculation to discriminate between PD-L1 low and high (22C3, 50%) with an AUC score of 0.779. Lastly, PD-L1 expression (28-8) did not show significant correlation with any detected oncogenic mutations, but negatively correlated with NKX2-1 gain ( p= 0.0379) and 9q deletion ( p= 0.0379) in ADCs. Conclusions: This study revealed the correlation between PD-L1 protein expression, clinical features, and mutational traits in NSCLC patients, and provided a classifier for PD-L1 expression prediction.
Royal College of Physicians
Journal: BMJ (1892)

英国皇家内科医师学会（The Royal College of Physicians，RCP）创建于1518年，是一个独立的专业会员制组织和慈善机构，机构设有临床标准部、全国性临床指南中心、交流和外事部、国际合作办公室和其他职能部门，目前拥有英国本土和国际会员25000多名。该学会以完善卫生保健系统、促进人类健康为宗旨，鼓励内科医生不断挑战新标准，增强自身技术、知识和能力，根据优质临床证据做出积极应变。
急性有机磷中毒80例
Authors: 孙逊, 桑荣霞
Journal: BMJ (2005)

急性有机磷中毒(acute organophosphorous pesticides poisoning, AOPP)死亡率较高,同等程度的中毒患者,中毒途径相同,抢救方式相似,结果可迥异.我院1996年8月至2004年7月共治疗AOPP患者80例,现报告如下。
发作性头痛-血压升高
Authors: 于微, 黄晓明, 黄程锦, 曾学军
Journal: BMJ (2007)

患者男,15岁.因发作性头痛伴血压升高10 d入院.2006年8月5日晚患者于睡眠中无明显诱因突发头痛,呈持续性,为双颞部搏动样胀痛.伴心悸,头部出汗,恶心呕吐2次,为非喷射样,呕吐物为胃内容物.无黑矇、视物模糊、头晕、耳鸣。
Comprehensive treatment for patients bitten by venomous snakes
Authors: 朱飚, 罗小林, 杨国清, 李平安
Journal: BMJ (2004)

目的 总结提高毒蛇咬伤抢救成功率的综合救治经验.方法 1993年1月～2002年12月共收治547例毒蛇咬伤患者,以应用精制抗蛇毒血清为主的综合治疗;治疗中注意肺、脑、肾、血液、循环功能的监护,早期发现、处理脏器受损;使用大剂量肾上腺皮质激素和山莨菪碱对抢救蛇伤患者提高临床疗效.结果治愈501例(91.6%);好转28例(5.1%);功能障碍8例(1.5%),其中植皮2例,截肢2例,截指(趾)3例,肢体偏瘫1例;死亡10例(1.8%).结论毒蛇咬伤致多器官衰竭是致死的高危因素,运用综合对症治疗可降低毒蛇咬伤的死亡率。
Network-meta-analysis of chemotherapy in nasopharyngeal carcinoma (MAC-NPC): An update on 8,221 patients.
Authors: Claire Petit, Anne WM Lee, Alexandra Carmel, Wai Tong Ng, Jun Ma, Anthony TC Chan, Ruey-Long Hong, Ming-Yuan Chen, Lei Chen, Guopei Zhu, Wen-Fei Li, Sharon Poh, Roger Ngan, Hai-Qiang Mai, Pei-Yu Huang, Li Zhang, George Fountzilas, Jean Bourhis, Jean-Pierre Pignon, Pierre Blanchard
Journal: Journal of Clinical Oncology (2020)

6523 Background: Based on an individual patient data (IPD) network meta-analysis (NMA) of 20 randomized trials and 5,144 patients (pts), the MAC-NPC collaborative group has shown that the addition of adjuvant chemotherapy (AC) to chemo-radiotherapy (CRT) achieved the highest survival benefit in nasopharyngeal carcinoma (NPC; Ribassin-Majed JCO 2017). Here, we updated the meta-analysis with the addition of 8 trials. Methods: Trials of Radiotherapy (RT) with or without chemotherapy (CT) in patients with non-metastatic NPC were identified and updated IPD obtained. Both Western and Chinese medical literatures were searched. Overall Survival (OS) was the main endpoint. Fixed and random-effects frequentist NMA models were applied, network heterogeneity and consistency were evaluated. P-score was used to rank the treatments. R software - netmeta package was used to perform the analyses. Treatments were grouped in the following categories: RT alone (RT), induction chemotherapy followed by RT (IC-RT), induction chemotherapy without taxanes followed by concomitant chemoradiotherapy (ICtax(-)-CRT), induction chemotherapy with taxanes followed by concomitant chemoradiotherapy (ICtax(+)-CRT), concomitant chemoradiotherapy (CRT), concomitant chemoradiotherapy followed by adjuvant chemotherapy (CRT-AC) and RT followed by adjuvant chemotherapy (RT-AC). Results: Overall 28 trials and 8,214 pts were included. Median follow-up was 7.2 years. There was no heterogeneity in the NMA. There was inconsistency in the main analysis, which disappeared after the exclusion of 2 outlier trials. ICtax(+)-CRT ranked the best treatment for OS with a P-Score of 91%. Hazard ratio [HR, 95% Confidence Interval] for ICtax(+)-CRT was 0.75 [0.59-0.96] compared to CRT and 0.92 [0.69-1.24] compared to CRT-AC (second best treatment in raking with a P-Score of 85%; see league table below). When the 2 types of IC were merged, CRT-AC ranked the first followed by IC-CRT with P-Scores of 93% and 86% respectively, with a HR of 0.97 [0.84-1.14] for CRT-AC vs. IC-CRT. Conclusions: This IPD NMA of the treatment of locally advanced NPC demonstrates that the addition of IC or AC to CRT improves disease control probability and survival over CRT alone. Data on progression-free survival, locoregional and distant control will be presented at the meeting. [Table: see text]
Differential expression of <i>KDM1A</i> and <i>SMAD7</i> genes in gliomas depending on the tumor grade.
Authors: Anton A. Pushkin, Ilya A. Alliluev, Eduard E. Rostorguev, Sergey E. Kavitskiy, Natalya S. Kuznetsova, Natalya N. Timoshkina, Oleg I. Kit
Journal: Journal of Clinical Oncology (2020)

e14549 Background: Gliomas are the most common type of primary brain tumors characterized by pronounced proliferation and aggressive infiltration. The purpose of the study was to analyze the expression of genes participating in the EGFR, TGF-B, HH/GLI, NOTCH and HIF1-alpha signaling pathways, transcription factors HBP1, MSI1/2 and demethylating agents in samples of various glioma types. Methods: The study included paired samples (tumor and physiologically unchanged neural tissue) obtained from 75 patients with histologically verified glial tumors of various grades (G2 - 21, G3 - 11, G4 - 43 patients). Relative expression of 15 genetic loci (EGFR, SMAD4, SMAD7, SMO, NOTCH1, NOTCH2, HBP1, HIF1A, EGLN1, EGLIN3, KDM1B, KDM1A, MSI1, MSI2, TET1) was measured by RT-qPCR. The PSMC, TBP and RPLO genes were used as the reference sequences. The 2 −ΔΔ Сt method was used to analyze the qPCR data. Statisical processing of the results was performed with the Statistica 10 program (StatSoft Inc., USA). Results: G2 gliomas showed a significant change in the relative expression of the KDM1A gene (p = 0.00572); G3 - a significant change in the relative expression of the HIF1A gene (p = 0.012726); G4 - significant changes in the relative expression of the EGFR (p = 0.021324), SMAD4 (p = 0.016534), SMAD7 (p = 0.000003), HBP1 (p = 0.003264), HIF1A (p = 0.007612), EGLN1 (p = 0.001623), EGLN3 (p = 0.004231) genes. Registered changes in the expression of the KDM1A and SMAD7 genes in the studied sample significantly differentiated the G2 and G4 glial tumors (p = 0.013 and p = 0.049, respectively). G2 tumors were characterized with increased expression of the KDM1A gene and decreased by more than 1.1 times in 95% of patients. 88% of patients with G4 tumors demonstrated no changes or a decrease in the KDM1A gene expression and decreased SMAD7 expression by more than 1.5 times. Conclusions: The established significant change in the expression of the KDM1A and SMAD7 genes depending on the tumor grade can be used for the differential diagnosis of gliomas.
Diagnosis and therapy of cyclomastopathy
Authors: Benzhong Wang, Gongsheng Jin
Journal: BMJ (2017)

乳腺增生症又名乳腺腺病、乳腺纤维囊性改变，是一种以乳腺疼痛为首发症状的常见乳腺良性病变。近年来随着人们对自我健康意识的提高，乳腺增生症开始受到广泛关注。然而，由于临床上缺乏相对应的认识，且疾病本身的发病机制尚不明确，因而其临床治疗方式较为混乱，亦无统一的评价指标。本文阐述乳腺增生症的病因、诊断、治疗的相关进展，为认识这一疾病开拓新的视野。
Immunoscore classifier:A gene based prognostic tool in early non-small cell lung cancer.
Authors: Meiying Guo, Xindong Sun, Jinming Yu, Linlin Wang
Journal: Journal of Clinical Oncology (2020)

e21030 Background: The clinical benefits of immunotherapy in patients with stage I non-small cell lung cancer (NSCLC) is still controversial. Immune status plays critical role in the development and progression of NSCLC, and is associated with the patient survival outcomes. The analysis of immune features is thus valuable for the determination of immunotherapy. However, one single immune feature cannot reflect the complex immune status, and its prognostic value is extremely limited. In this study, we aimed to construct an immunoscore classifier based on multiple immuno-genes to predict the prognosis of patients with early NSCLC. Methods: A total of 522 patients with stage I NSCLC were included in this study. All patients' follow-up records and gene expression data were completely preserved. A least absolute shrinkage and selection operator (LASSO) algorithm was used to screen immune-related genes, and a COX proportional hazard regression model was used to construct the immunoscore classifier based on multiple immune-genes. Besides, the net reclassification improvement (NRI) calculation and concordance index (C-index) were applied to quantify the improvement of usefulness added by the immunoscore classifier compared to TNM staging system. Results: The immunoscore classifier including CCL5, CD8A, CXCL9, HLA-DQA1, LAG3, STAT1, and CD276 was significantly correlated with OS (HR: 2.785 CI: 1.809-4.289 P &lt; 0.001) in patients with stage I NSCLC. With the optimal cut-off value of 4.32, all patients can be divided into a low-risk immune group and a high-risk immune group. The 10-year survival rates of the two groups were 36.8% and 12.3%, respectively. Besides, the immunoscore classifier was superior to the traditional TNM staging system in terms of distinguishing ability (C-index improvement by 0.075) and net reclassification ability (NRI improvement by 11.29%), indicating that the immunoscore classifier plays an important role in improving prognostic value. Conclusions: Multiple immune-genes based immunoscore classifiers can effectively predict the prognosis of patients with stage I NSCLC, and is significantly superior to the traditional TNM staging system in terms of prediction effectiveness and accuracy. As a new assessment tool, the immunoscore classifier may be helpful for determining the immune status of patients with stage I NSCLC and screening patients suitable for subsequent immunotherapy.
Effectively implementation of prevention and control for COVID-19 vinus infection in primary care
Authors: Chunhua Chi, Hao Wu, Ting Yang, Chen Wang
Journal: BMJ (2020)

为强化和规范基层新型冠状病毒感染的防控工作，由中华医学会、中国医师协会相关专业分会的专家联合制订了《新型冠状病毒感染基层防控指导意见（第一版）》，从基层医疗卫生机构防控规范、普通人群防控规范、特殊人群防控规范、科普宣教、信息技术应用等方面给予了详细的指导。旨在促进基层医疗卫生机构和基层医务人员在抗击新型冠状病毒感染疫情阻击战中，承担起居民健康守门人的职责，扎扎实实做好科学有效的防控工作，从根本上保障全民健康。